

1 December 2023

ASX Code: MXC

LSE Code: MXC

Corporate Update - Board and UK Adviser Changes

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd (**MGC Pharma, MGC** or the **Company**), a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, announces the following changes to the Board and its UK Broker.

Mr Daniel Robinson has been appointed as a Non-Executive Director of the Company effective immediately. Mr Robinson has over 20 years' experience in a broad range of corporate roles across stockbroking, corporate advisory, investor relations and governance. He is an experienced Company Secretary and Director of both private and listed companies. Additionally, Mr Robinson is a Member of the Australian Institute of Company Directors.

Dr Stephen Parker and Dr Ross Walker will be stepping down from the Board to pursue other opportunities. The Company would like to thank Dr Parker and Dr Walker for all their contributions throughout their tenure and wish them all the best in their future endeavours.

In addition, CMC Markets UK PLC (**CMC**) has been appointed as the Company's joint UK broker with immediate effect. CMC Markets is a UK-based financial services company that offers online trading in shares, spread betting, contracts for difference (CFDs) and foreign exchange across world markets. CMC is headquartered in London, with hubs in Sydney and Singapore. CMC is listed on the London Stock Exchange and was admitted to the FTSE 250 on 20 June 2016.

-ENDS-

Authorised for release by the board of directors, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@mgcpharma.co.uk

UK IR/PR Advisers

IFC Advisory
Graham Herring / Tim Metcalfe / Zach Cohen
+44 203 934 6630
mgcpharma@investor-focus.co.uk

MGC Pharmaceuticals Ltd

Rowan Harland
Company Secretary
+61 8 6555 2950
info@mgcpharma.co.uk

UK Brokers

Oberon Capital
Aimee McCusker / Adam Pollock
+44 203 179 5300
aimeemccusker@oberoninvestments.com
adampollock@oberoninvestments.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma